Clik here to view.
迪拜卫生署部署Masimo Patient SafetyNet™
阿拉伯联合酋长国迪拜 (美国商业资讯) — Masimo (NASDAQ:MASI)今天宣布，迪拜卫生署(DHA)已在迪拜市的两家医院部署Masimo Patient SafetyNet™*，DHA是监管迪拜医疗保健系统的政府组织，此举扩大了该署现有的Masimo设备和技术目录。Patient SafetyNet是一种辅助的远程监护和临床工作人员通知系统。...
View ArticleClik here to view.
CDISC Releases Therapeutic Area User Guide to Assist in Discovery of New...
AUSTIN, Texas According to the World Health Organization, prostate cancer is one of the five most common types of cancer to affect men globally. In an effort to improve research for prostate cancer,...
View ArticleClik here to view.
New Data Shows Previously Allergic Children Still Able to Tolerate Peanut...
MELBOURNE, Australia Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota) is pleased to announce results from a follow up study of the probiotic and peanut immunotherapy (PPOIT)...
View ArticleClik here to view.
Ligand to Receive $2 Million from WuXi Biologics for Licensing Clinical-Stage...
SAN DIEGO Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand” or “the Company”) announces that it will receive a $2 million payment from WuXi Biologics subsequent to their licensing of...
View ArticleClik here to view.
Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to...
INCHEON, Korea Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company Limited (TSE: 4502) to jointly fund and...
View ArticleClik here to view.
PREVENA™ Incision Management System Shown to Reduce Incisional Pain and...
SAN ANTONIO Recent results published in the American Journal of Perinatology demonstrated the reduction of post-surgical wound complications in obese patients undergoing cesarean delivery with...
View ArticleClik here to view.
PAREXEL and Osaka International Cancer Institute Form Alliance to Advance...
BOSTON & OSAKA, Japan PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, and Osaka International Cancer Institute today announced that they...
View ArticleClik here to view.
Anatara与硕腾商谈Detach®国际商业协议条款
澳大利亚布里斯班 (美国商业资讯) — Anatara Lifesciences (ASX:ANR)欣然宣布，全球性动物保健公司硕腾(Zoetis Inc.)已行使期权，商谈Detach®全球开发、经销和市场营销的商业协议，各项条款有待达成。 Smart News Releases（智能新闻稿）是一个多媒体平台。在此处查看完整新闻稿：...
View ArticleClik here to view.
Can-Fite Receives Milestone Payment From CKD Pharmaceuticals its Distribution...
PETACH TIKVA, Israel Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address cancer, liver and...
View ArticleClik here to view.
Celularityが画期的な胎盤発見＆治療プラットフォームの開発を促進
米ニュージャージー州ウォーレン （ビジネスワイヤ） — 最近創業したバイオテクノロジー企業のCelularity,...
View ArticleClik here to view.
未治療患者におけるNuwiq®の低免疫原性と優れた効力を実証する臨床データを公表
スイス・ラッヘン （ビジネスワイヤ） — オクタファルマは、未治療患者（PUP）をNuwiq®で治療する初の臨床試験となるNuProtect試験（GENA-05、NCT01712438）について、中間データが2017年8月16日に国際的に著名な医学誌「ヘモフィリア」の先行公開論文として公表されたことを発表します。...
View ArticleClik here to view.
Celularity, Inc.加快突破性胎盘发现和治疗平台
新泽西州沃伦 (美国商业资讯) — Celularity, Inc.是一家新成立的生物技术公司，该公司今天宣布，它在加快细胞及组织再生治疗药物，以满足癌症和慢性及退行性疾病领域未获满足的医疗需求。Celularity已完成A轮融资，投资方来自数家生物制药公司，包括Sorrento Therapeutics、United Therapeutics Corporation和Human...
View ArticleClik here to view.
已发表的临床数据显示，Nuwiq®对既往未曾治疗的患者免疫原性低、有效性卓著
瑞士拉亨 (美国商业资讯) — Octapharma欣然宣布，NuProtect研究(GENA-05, NCT01712438)的中期数据已经发表：Nuwiq®治疗既往未曾治疗的患者(PUP)的首批临床数据于2017年8月16日作为预览论著发表于国际著名的医学杂志《血友病》(Haemophilia)。 NuProtect研究启动于2013年3月，旨在研究Nuwiq® 对重症血友病A...
View ArticleClik here to view.
Astex Pharmaceuticals Celebrates as Cancer Drug Receives Marketing Approval...
CAMBRIDGE, England Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central...
View ArticleClik here to view.
Samsung Bioepis First to Obtain European Commission Approval for a Third...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced the European Commission’s (EC) approval of Imraldi®, a biosimilar referencing Humira® 1 (adalimumab), for the treatment of rheumatoid...
View ArticleClik here to view.
Kyowa Hakko Kirin Co., Ltd.: US Food and Drug Administration Grants...
TOKYO Kyowa Hakko Kirin Co., Ltd. (TOKYO:4151)(President and CEO: Nobuo Hanai, “Kyowa Hakko Kirin”) today announced that U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy...
View ArticleClik here to view.
GRAMINEX L.L.C.在韩国首尔开张新办事处Graminex Korea Co., Ltd.
密歇根州萨基诺 (美国商业资讯)–Graminex® Flower Pollen Extracts™的生产商Graminex® LLC欣然宣布，Graminex® Korea Co., Ltd.开张。Sun-Ho Frank Kim博士被任命为韩国首尔当地办事处的董事总经理。 Sun-Ho Frank...
View ArticleClik here to view.
グラミネックス、韓国ソウルに新事務所「グラミネックス・コリア」を開設
米ミシガン州サギノー （ビジネスワイヤ）– グラミネックス花粉エキスを生産するグラミネックス（Graminex® LLC）は、グラミネックス・コリアの開設を発表します。キム・スンホ・フランク博士（Ph.D.）が韓国ソウルの現地事務所のマネジングディレクターに任命されました。...
View ArticleClik here to view.
From Genetic Genealogy to Rapid DNA Analysis and MPS, Explore Real-Word...
MADISON, Wis. The 28th International Symposium on Human Identification (ISHI) will feature presentations from leading professionals in the fields of forensic DNA analysis, genetic genealogy,...
View ArticleClik here to view.
Avita Medical Names Erin Liberto as Chief Commercial Officer
VALENCIA, Calif. & PERTH, Australia & LONDON Avita Medical, Ltd. (ASX: AVH), (OTCQX: AVMXY), a medical device company developing innovative therapeutic solutions derived from the...
View Article